Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Malcolm Spicer

Malcolm Spicer, Managing Editor – US

Washington, DC
Malcolm Spicer is lead analyst for Pharma intelligence | informa's coverage of the consumer health care products industries. He provides comprehensive and insightful reporting on manufacturing, marketing, regulation, legislation, financial and research news about the nonprescription drug and nutritional product industries. He has worked in this post for 10 years and previously reported for other publications on regulation of the health care industry, on the telecommunications and internet technologies and on the US energy market.

Latest From Malcolm Spicer

In Rare Cannabinoids, BioMedican Sees Alphabet Of Potential Dietary And Drug Ingredients

BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.

Cannabidiol CBD Dietary Supplements

‘Pharmaceutical’ Controls, Lower Costs: Future Of Cannabinoid Ingredients In Biosynthesis?

Synthetics are necessary for drugs containing cannabinoids because the active ingredient must be consistent from dose to dose. Cannabinoids extracted from hemp vary from plant to plant and more widely from crop to crop, but consistency should matter for cannabinoids used as dietary ingredients, says BioMedican president Dennis O’Neill.

Cannabidiol CBD Dietary Supplements

US FDA’s 30-Day Extension For Nitrosamine Assessments Short Of Industry Recommendation

Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.

OTC Drugs Guidance Documents

With Timetable In Hand And Icahn On Board, Bausch Health Looks To ‘Expedite Spin-Off’

Executives say Bausch + Lomb spin-out preparations will be completed by the end of Q3. When asked, they elaborated on Carl Icahn’s acquisition of 27.8m shares, for a 7.8% stake, and expansion of the firm’s board by two seats for Icahn’s representatives.

Sales & Earnings M & A

IFF Plus DuPont N&B Equals $11.2Bn Revenues

"Now it's up to us to look where can we accelerate our portfolio, in which areas and where can we grow the most and deliver good value for our customers,” says CEO Andreas Fibig.

Dietary Supplements M & A

‘Uniquely Positioned’ In Probiotics, IFF Emphasizes Ingredients For Women's, Cognitive, Skin Health

Jennifer Montgomery, IFF’s probiotics marketing manager for the Americas, responds to HBW Insight questions about the firm’s plans to deliver probiotics ingredients and technologies following the recent closing of its acquisition of DuPont Nutrition & Biosciences through a merger agreement.

Dietary Supplements Research & Development
See All
UsernamePublicRestriction

Register